-

10:56:48 AM

STOK Stock News

STOK - Stoke Therapeutics Inc

04/05/22 7:30 AM

Nasdaq : STOK

conferenceslow float

Stoke Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference

Stoke Therapeutics, Inc., a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022, at 8:00 a.m. ET. About Stoke Therapeutics Stoke...

RHEA-AI

neutral

03/10/22 7:00 AM

Nasdaq : STOK

earningslow float

Stoke Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates

Stoke Therapeutics, Inc., a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the full year ended December 31, 2021 and provided business updates. “During the past year, the Stoke team made significant progress with...

RHEA-AI

neutral

02/28/22 7:30 AM

Nasdaq : STOK

conferenceslow float

Stoke Therapeutics to Participate in the Cowen 42nd Annual Health Care Conference

Stoke Therapeutics, Inc., a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will participate on the Orphan Neuro Panel at the Cowen 42nd Annual Health Care Conference on Monday, March 7, 2022, at 9:10 a.m. ET.

RHEA-AI

neutral

01/19/22 7:00 AM

Nasdaq : STOK, ALNY

low float

Ceptur Therapeutics Launches with $75M Series A Financing to Advance RNA Therapeutics Based on Proprietary U1 Adaptor Technology

Ceptur Therapeutics, Inc., a biotechnology company focused on developing targeted oligonucleotide therapeutics based on U1 Adaptor technology, today announced the completion of a $75 M Series A financing. The round was co-led by venBio Partners and Qiming Venture Partners USA with participation by new investors Perceptive Xontogeny Venture Fund,...

RHEA-AI

positive

01/10/22 7:00 AM

Nasdaq : ACAD, STOK

Acadia Pharmaceuticals and Stoke Therapeutics Announce Collaboration to Pursue Multiple RNA-based Treatments for Severe and Rare Genetic Neurodevelopmental Diseases

Acadia Pharmaceuticals Inc. and Stoke Therapeutics, Inc. announced today that the companies have entered a collaboration to discover, develop and commercialize novel RNA-based medicines for the...

RHEA-AI

neutral

01/04/22 7:30 AM

Nasdaq : STOK

conferenceslow float

Stoke Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

Stoke Therapeutics, Inc., a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022, at 4:30 p.m. ET. Stoke Therapeutics, is a...

RHEA-AI

neutral

12/03/21 10:00 AM

Nasdaq : STOK

clinical triallow float

Stoke Therapeutics Presents Data from the Phase 1/2a MONARCH Study of STK-001 in Children and Adolescents with Dravet Syndrome at the American Epilepsy Society (AES) 2021 Annual Meeting

Stoke Therapeutics, Inc., a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced highlights from five presentations related to the ongoing clinical development of STK-001 being made at the American Epilepsy Society 2021 Annual Meeting,...

RHEA-AI

neutral

11/19/21 11:54 AM

Nasdaq : STOK

low float

Stoke Therapeutics Announces Presentations from the Company’s Dravet Syndrome Program at the American Epilepsy Society 2021 Annual Meeting

Stoke Therapeutics, Inc., a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that five abstracts related to the Company’ s work in Dravet syndrome will be presented at the American Epilepsy Society 2021 Annual Meeting, taking place December...

RHEA-AI

neutral

11/08/21 7:00 AM

Nasdaq : STOK

earningslow float

Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates

Stoke Therapeutics, Inc., a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the third quarter of 2021 and provided business updates. “The recent positive interim data from the Phase 1/ 2 a MONARCH study in patients with...

RHEA-AI

neutral

11/03/21 7:30 AM

Nasdaq : STOK

conferenceslow float

Stoke Therapeutics to Present at Upcoming Investor Conferences in November

Stoke Therapeutics, Inc., a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at two upcoming investor conferences in November. Stifel 2021 Virtual Healthcare Conference Date: Monday, November 15, 2021 Time:...

RHEA-AI

neutral

Prev 1 2 3 4 5 6 Next

STOK Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.stoketherapeutics.com
CeoEdward Kaye
Security nameStoke Therapeutics Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees117
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address3 Preston Ct
StateMassachusetts
CityBedford
Zip01730-2379
CountryUS
Phone17814308200

About Stoke Therapeutics Inc

Stoke Therapeutics, is a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines. Using the company's proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach Stoke is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. The company's first compound, STK-001 is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. Dravet syndrome is one of many diseases caused by a haploinsufficiency, in which a loss of ~50% of normal protein levels leads to disease. The company is pursuing treatment for a second haploinsufficient disease, autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. Stoke's initial focus is haploinsufficiencies and diseases of the central nervous system and the eye, although proof of concept has been demonstrated in other organs, tissues, and systems, supporting the company's belief in the broad potential for its proprietary approach. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts.